(株)メドレックスの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証GRT | 医薬品 | 4586/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2014/05/30 | 日証協 | 782,701株 | -1.94% | 51,901株 | -21.84% | 555,944株 | +1.72% | 26,000株 | -11.86% |
2014/05/23 | 日証協 | 798,201株 | +3.85% | 66,400株 | +262.84% | 546,544株 | +2.61% | 29,500株 | +172.9% |
2014/05/16 | 日証協 | 768,601株 | +2.15% | 18,300株 | +59.13% | 532,644株 | +0.87% | 10,810株 | +10.23% |
2014/05/09 | 日証協 | 752,401株 | +0.05% | 11,500株 | -79.75% | 528,027株 | +0.36% | 9,807株 | +78.31% |
2014/05/02 | 日証協 | 752,001株 | +9.3% | 56,800株 | +56.47% | 526,127株 | -6.29% | 5,500株 | -58.65% |
2014/04/25 | 日証協 | 688,001株 | +3.15% | 36,300株 | -65.98% | 561,427株 | +2.46% | 13,300株 | -77.83% |
2014/04/18 | 日証協 | 667,001株 | +20.12% | 106,700株 | +283.81% | 547,927株 | +16.23% | 60,000株 | -13.17% |
2014/04/11 | 日証協 | 555,301株 | -0.41% | 27,800株 | +5460% | 471,427株 | +15.09% | 69,100株 | +5658.33% |
2014/04/04 | 日証協 | 557,601株 | -9.19% | 500株 | -99.44% | 409,627株 | -3.17% | 1,200株 | -96.35% |
2014/03/28 | 日証協 | 614,001株 | +14% | 89,500株 | +4161.9% | 423,031株 | +6.79% | 32,900株 | +1072.07% |
2014/03/20 | 日証協 | 538,601株 | -24.44% | 2,100株 | -83.46% | 396,131株 | -2.63% | 2,807株 | -80.52% |
2014/03/14 | 日証協 | 712,801株 | +0.75% | 12,700株 | -49.2% | 406,824株 | +2.21% | 14,407株 | -43.5% |
2014/03/07 | 日証協 | 707,501株 | -0.11% | 25,000株 | -43.18% | 398,017株 | +3.91% | 25,500株 | -58.2% |
2014/02/28 | 日証協 | 708,301株 | +0.63% | 44,000株 | +178.48% | 383,024株 | +5.6% | 61,000株 | +175.96% |
2014/02/21 | 日証協 | 703,901株 | -0.52% | 15,800株 | -33.89% | 362,724株 | +3.69% | 22,105株 | -26.56% |
2014/02/14 | 日証協 | 707,601株 | +4.14% | 23,900株 | -91.48% | 349,818株 | +6.91% | 30,101株 | -19.11% |
2014/02/07 | 日証協 | 679,501株 | +33.89% | 280,600株 | +460.08% | 327,218株 | -21.94% | 37,210株 | -33.74% |
2014/01/31 | 日証協 | 507,501株 | +3.95% | 50,100株 | -42.48% | 419,208株 | +5.98% | 56,160株 | +114.35% |
2014/01/24 | 日証協 | 488,201株 | +2.52% | 87,100株 | +400.57% | 395,558株 | +11.69% | 26,200株 | -39.21% |
※株式分割は考慮していませんのでご注意ください。
Page Top